It should be noted, for example, that dozens of Risperdal lawsuits have been filed on behalf of children who allegedly suffered gynecomastia and other serious complications due to their use of this medication.
New York, New York (PRWEB) September 15, 2014
As Risperdal lawsuits (http://www.injurybeacon.com/risperdal/lawsuit/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that a new study has proposed that the antipsychotic medication might be useful in curbing aggression in children with ADHD when it is taken in conjunction with a stimulant and parent training in behavioral management techniques. According to a report from HealthDay News, the study involved 170 children with ADHD and aggression problems, half of whom took Concerta, a stimulant widely prescribed to treat ADHD, in conjunction with parent training techniques to manage aggressive behaviors. The other half received the same therapy, but it was augmented by Risperdal. *
After nine weeks, improvement was seen in both groups. However, parents reported that children on augmented therapy were less likely to be impaired socially or academically by their aggression issues. Despite the encouraging results, the authors of the study did note that long-term evidence is needed indicating that combining Concerta and Risperdal is safe in children.
“This study is interesting, but its authors were correct to suggest that more long-term safety evidence is needed. It should be noted, for example, that dozens of Risperdal lawsuits have been filed on behalf of children who allegedly suffered gynecomastia and other serious complications due to their use of this medication,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal.
Risperdal Litigation
Risperdal is currently not approved to treat children with ADHD. However, the U.S. Food & Drug Administration (FDA) has cleared the medication to treat adult and adolescent schizophrenia, bipolar disorder in adults and children ages 10-to-17, and irritability in children (5-to-16 years of age) with autistic disorder.**
According to court documents, more than 700 Risperdal lawsuits are currently pending in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, where Bernstein Liebhard LLP is actively filing claims. All of these complaints, many of which were filed on behalf of children, allege that the medication caused serious side effects, including gynecomastia in boys. The lawsuits also accuse Johnson & Johnson and Janssen Pharmaceuticals of concealing these risks, and of improperly marketing the drug for unapproved uses, including for the treatment of children long before any of its pediatric indications were approved in 2006. (In Re: Risperdal Litigation, Case Number 100300296).
In November 2013, Johnson & Johnson and Janssen Pharmaceuticals agreed to pay $2.2 million to settle charges brought by the U.S. Department of Justice involving the marketing of Risperdal and other medications. While the companies did not admit any wrongdoing in resolving civil charges regarding the promotion of Risperdal for off-label use in children, they did plead guilty to a criminal misdemeanor and acknowledged that they had improperly marketed the drug for use in elderly dementia patients. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Men and boys who allegedly developed gynecomastia due to Risperdal may be entitled to take legal action against the manufacturers of the medication. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
*wbtv.com/story/26509358/medications-plus-parent-training-may-help-kids-with-aggression-adhd, HealthDay News, September 11, 2014
**http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, Risperdal Prescribing Information, FDA, 2009
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.injurybeacon.com/
https://plus.google.com/115936073311125306742?rel=author